Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 208, Issue 6, Pages 1215-1228Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20102177
Keywords
-
Categories
Funding
- UK Medical Research Council
- Royal Society
- MRC
- US National Institutes of Health [DK 176743]
- MRC [MC_U127081014, MC_U127084348] Funding Source: UKRI
- Medical Research Council [MC_U127081014, MC_U127084348] Funding Source: researchfish
Ask authors/readers for more resources
The protein ABIN1 possesses a polyubiquitin-binding domain homologous to that present in nuclear factor kappa B (NF-kappa B) essential modulator (NEMO), a component of the inhibitor of NF-kappa B (I kappa B) kinase (IKK) complex. To address the physiological significance of polyubiquitin binding, we generated knockin mice expressing the ABIN1[D485N] mutant instead of the wild-type (WT) protein. These mice developed all the hallmarks of autoimmunity, including spontaneous formation of germinal centers, isotype switching, and production of autoreactive antibodies. Autoimmunity was suppressed by crossing to MyD88(-/-) mice, demonstrating that toll-like receptor (TLR)-MyD88 signaling pathways are needed for the phenotype to develop. The B cells and myeloid cells of the ABIN1[D485N] mice showed enhanced activation of the protein kinases TAK, IKK-alpha/beta, c-Jun N-terminal kinases, and p38 alpha mitogen-activated protein kinase and produced more IL-6 and IL-12 than WT. The mutant B cells also proliferated more rapidly in response to TLR ligands. Our results indicate that the interaction of ABIN1 with polyubiquitin is required to limit the activation of TLR-MyD88 pathways and prevent autoimmunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available